Zhitong Finance App News, Maiwei Bio-B (02493.HK) issued an announcement. Recently, Maiwei (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as the “Company”) received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, and the clinical trial application for 9MW5211 injection for primary biliary cholangitis (PBC) indications was approved. Previously, its clinical trial application for inflammatory bowel disease (IBD) indications had been approved by the China Drug Administration and FDA approval for multiple sclerosis, respectively. (MS ), clinical trial applications for type 1 diabetes (T1DM), and vitiligo indications have been approved by the State Drug Administration; the company is also actively promoting clinical trial applications for other indications.

Zhitong Finance App News, Maiwei Bio-B (02493.HK) issued an announcement. Recently, Maiwei (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as the “Company”) received the “Drug Clinical Trial Approval Notice” approved by the State Drug Administration, and the clinical trial application for 9MW5211 injection for primary biliary cholangitis (PBC) indications was approved. Previously, its clinical trial application for inflammatory bowel disease (IBD) indications had been approved by the China Drug Administration and FDA approval for multiple sclerosis, respectively. (MS ), clinical trial applications for type 1 diabetes (T1DM), and vitiligo indications have been approved by the State Drug Administration; the company is also actively promoting clinical trial applications for other indications.